Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
about
Chemoresistance and targeted therapies in ovarian and endometrial cancersThe pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noisep53 Family and Cellular Stress Responses in Cancer.Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARβ2 and RASSF1A demethylationEnrichment Analysis Identifies Functional MicroRNA-Disease Associations in HumansMiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy.Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.Exosomes as mediators of platinum resistance in ovarian cancer.Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.Targeting p53-MDM2-MDMX loop for cancer therapy.The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer.Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancerTherapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor - LQFM030.Establishment of a SVM classifier to predict recurrence of ovarian cancer
P2860
Q28073246-276A2158-3A03-4B2D-9787-E18A99E1917DQ28542661-B3C2611D-527E-4ADE-842E-0878C891A4EFQ34377287-39DADE1D-675F-4C96-8780-D303C3C8FDD4Q34835780-167C9BAF-E281-4898-9806-4F17DCF04F4DQ35752431-7198B3DC-8401-4D83-B9DE-0490981976BAQ35919064-D88A6592-3942-4E79-950A-26ED30A39DD1Q36604270-E23BDB26-BFCB-472E-86E2-C899D12E2D56Q37457809-E1FC62A7-E286-4184-A35D-C25CDA3E59A4Q37707018-D5679390-1EC4-41BD-A5BB-756059EE4260Q38145508-A74F50DB-4F49-4530-ABB7-E5485D121C9DQ38247168-B9086F53-EC4C-4FDF-82BA-DA854EC271F2Q38635932-D2565EB0-6028-4395-8B49-3817F5C0335DQ38845519-BAA8B757-0E1F-4A8E-BC34-EEDF6384DFD6Q38858580-76DC5921-B735-48BD-B061-50399AB058B1Q39464301-7D5B4179-00D7-4182-B869-864311BC4629Q42378380-A44C37E5-CC5D-41E6-AD60-97A6809771F4Q50200634-FB81B8F1-AB39-4365-8EBF-081AEDFFC4BAQ58794937-EB674254-9937-474D-AE88-603AB6C8EBB8
P2860
Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Mdm2 antagonists induce apopto ...... ild-type ovarian cancer cells.
@en
Mdm2 antagonists induce apopto ...... ild-type ovarian cancer cells.
@nl
type
label
Mdm2 antagonists induce apopto ...... ild-type ovarian cancer cells.
@en
Mdm2 antagonists induce apopto ...... ild-type ovarian cancer cells.
@nl
prefLabel
Mdm2 antagonists induce apopto ...... ild-type ovarian cancer cells.
@en
Mdm2 antagonists induce apopto ...... ild-type ovarian cancer cells.
@nl
P2093
P2860
P50
P356
P1476
Mdm2 antagonists induce apopto ...... ild-type ovarian cancer cells.
@en
P2093
Alba Pérez-Perarnau
Enric Condom
Fina Martinez-Soler
Tatiana Ruiz-Larroya
P2860
P304
P356
10.1002/IJC.27832
P577
2012-10-11T00:00:00Z